Study shows ivarmacitinib safe, efficacious in treating moderate-to-severe AD

According to a recent study, ivarmacitinib, a Januse kinase (JAK)-1 inhibitor, has been shown to be effective and safe in treating adolescent and adult patients with atopic dermatitis (AD).